This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

77/100

✓ Peer-reviewed alzhub usefulness score 77 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Results Of a total 912 participants, there were 499 males (54.7%) and 413 females (45.3%), and the mean (SD) age was 71.1 (8.49) years. Among the biomarkers, plasma p-tau217 was most strongly associated with Aβ positivity (test-set area under the receiver operating characteristic curve [AUC] = 0.94; 95% CI, 0.90-0.97). This procedure had an overall sensitivity of 0.94 (95% CI, 0.90-0.98) and a specificity of 0.86 (95% CI, 0.77-0.95). Plasma p-tau217 again performed best, with the test AUC = 0.92 (95% CI, 0.86-0.97), without significant improvement when adding any of the other plasma biomarkers. The results were validated in an independent cohort (n = 118).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Mattsson-Carlgren, N., Collij, L. E., Stomrud, E., Pichet Binette, A., Ossenkoppele, R., Smith, R., et al. (2024). Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2023.4596

Vancouver

Mattsson-Carlgren N, Collij LE, Stomrud E, Pichet Binette A, Ossenkoppele R, Smith R, et al. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. JAMA Neurology. 2024. doi:10.1001/jamaneurol.2023.4596. PMID: 38048096.

BibTeX

@article{mattssoncarlgren2024-38048096,
  author  = {Mattsson-Carlgren, N. and Collij, L. E. and Stomrud, E. and Pichet Binette, A. and Ossenkoppele, R. and Smith, R. and Karlsson, L. and Lantero-Rodriguez, J. and Snellman, A. and Strandberg, O. and Palmqvist, S. and Ashton, N. J. and others},
  title   = {{Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies}},
  journal = {JAMA Neurology},
  year    = {2024},
  doi     = {10.1001/jamaneurol.2023.4596},
  pmid    = {38048096},
  url     = {https://doi.org/10.1001/jamaneurol.2023.4596}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Results Of a total 912 participants, there were 499 males (54.7%) and 413 females (45.3%), and the mean (SD) age was 71.1 (8.49) years.
Among the biomarkers, plasma p-tau217 was most strongly associated with Aβ positivity (test-set area under the receiver operating characteristic curve [AUC] = 0.94; 95% CI, 0.90-0.97).
This procedure had an overall sensitivity of 0.94 (95% CI, 0.90-0.98) and a specificity of 0.86 (95% CI, 0.77-0.95).
Plasma p-tau217 again performed best, with the test AUC = 0.92 (95% CI, 0.86-0.97), without significant improvement when adding any of the other plasma biomarkers.
The results were validated in an independent cohort (n = 118).

Why it matters

Plasma p-tau217 was most strongly associated with amyloid positivity and performed best among the biomarkers tested, with high sensitivity and specificity, and results were validated in an independent cohort. This suggests plasma p-tau217 could help select patients with Alzheimer's disease for antiamyloid immunotherapies.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designcohort
Participants912
Effect sizeAUC 0.94 for amyloid status; 56.9% of tau PET scans avoidable
Evidence strengthHigh

How this study scored 77/100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomised / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 75 of the 98 points we could judge it on, which is 77 out of 100.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (JAMA Neurology)
Journal's citation record	2 / 4	JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	2 / 4	912 participants
Effect reported	3 / 3	Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 147 times (OpenAlex, 2026-10-10)
Citations per year	4 / 5	36.8 citations a year over 4 year(s) since 2024
Impact for its field and year	5 / 6	Cited 26.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	3 / 6	Cited by 22 other studies in this library
Still being cited	3 / 4	Cited 146 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career)
Institution's track record	1 / 3	King's College London: institution h-index 1,348 (OpenAlex)
Multi-centre collaboration	3 / 3	OpenAlex lists 11 institution(s) in 5 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 38048096)
Free to read	— / 2	Access not recorded — left out of this score
Points	75 / 98	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 75 of the 98 points we could judge it on is 77 out of 100.
Total	77 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.

Later studies that cite this one

22 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Biomarkers

Also tagged “cerebrospinal”

821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Similar studies

More on Biomarkers

See all studies in Biomarkers →